Trials / Conditions / Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
4 registered clinical trials studyying Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373 | Mayo Clinic | Phase 2 |
| Recruiting | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088 | David Bond, MD | Phase 2 |
| Active Not Recruiting | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672 | National Cancer Institute (NCI) | Phase 2 |